Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biora AB Elects Lars Ingelmark to its Board of Directors at Annual Shareholders Meeting.


MALMO, Sweden--(BUSINESS WIRE)--April 29, 1999--

Biora AB (Nasdaq:BIORY)(SSE (1) An earlier full-screen editor in OS/2.

(2) (Streaming SIMD Extensions) A series of additional instructions built into Pentium CPU chips for improved multimedia performance by performing mathematical operations on multiple sets of data at the
:BIOR) today elected Lars Ingelmark, Head of AP Life Science Ventures, on the Swedish National Pension Fund, 6th Fund Board, to its Board of Directors at the Company's annual shareholders meeting.

The Board of Directors now consists of Per Wahlstrom, Svein G. Eskedal, Tomas Hammargren, Lars Hammarstrom, Bertil Koch Koch , Robert 1843-1910.

German bacteriologist who discovered the cholera bacillus and the bacterial cause of anthrax. He won a 1905 Nobel Prize for developing tuberculin.



Koch

named after Robert Koch, a German bacteriologist.
, Per Lojdquist and Toni Weitzberg.

The meeting also decided that no dividend would be paid for the 1998 fiscal year.

Biora develops, manufactures, markets and sells products for the treatment of periodontal disease Periodontal Disease Definition

Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where
 and for use in oral surgery. Using its proprietary technology and expertise, Biora aims to become a world leader in biology-based products for specialized spe·cial·ize  
v. spe·cial·ized, spe·cial·iz·ing, spe·cial·iz·es

v.intr.
1. To pursue a special activity, occupation, or field of study.

2.
 dental therapy.

This press release may contain certain forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.

Note to Editors: In the second paragraph, the last names "Wahlstrom," "Hammarstrom," and "Lojdquist" contain an umlaut umlaut (m`lout) [Ger.,=transformed sound], in inflection, variation of vowels of the type of English man to men.  over the letter "o." Also, the city "Malmo" contains an umlaut over the letter "o." The umlauts were omitted for transmission purposes only.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUSW
Date:May 3, 1999
Words:238
Previous Article:Jones Naughton Entertainment Announces Three New Internet Kiosk Sites.
Next Article:Generation Entertainment's Millennium Division Announces European Promotional Tour.
Topics:



Related Articles
Biora Starts New Subsidiary for Research and Development of Products for Use Outside the Oral Cavity.
Biora AB Interim Report, First Quarter 1999.
Biora AB Elects Lars Ingelmark to its Board of Directors at Annual Shareholders Meeting.
Biora AB Interim Report, First Quarter 1999.
Biora AB Issues Half Year Report.
Biora's Principal Product Emdogain Gained Recognition At Specialist-Conference In The United States.
Biora AB Malmo, Sweden Releases Q3 Report.
Biora's Preclinical Studies Show That The Company's Main Product, Emdogain, Induces Cell Death In Human Cancer Cells.
Rickard Soderberg new CEO for Biora AB.
Biora AB Reports For the First Quarter 2001.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles